Novel Diabetes Medications and Retinopathy Recording-Novel Diabetes Medications and Retinopathy Recording

Video Transcription

Video Summary

In a detailed webinar hosted by the Diabetes Technology Interest Group, experts discussed the use and implications of novel diabetes medications like GLP-1 and SGLT2 on diabetic retinopathy. Dr. Andrew Barkmeyer, an ophthalmologist at the Mayo Clinic, shared insights on these medications' cardiovascular benefits and their complex relationship with retinopathy. Despite initial concerns over the potential for these medications to exacerbate diabetic retinopathy, Barkmeyer emphasized long-term systemic benefits and recommended closer monitoring rather than delaying treatment. The webinar also examined the nuanced impacts of these drugs on other ocular conditions, such as the rare non-arteritic ischemic optic neuropathy, and explored evolving treatments, like the potential use of fenofibrate to manage retinopathy progression. Attendees were urged to maintain strong communication across medical disciplines to manage diabetic patients optimally. The session also highlighted the importance of regular eye exams to catch complications early, maintaining that advancements in systemic and ocular treatments are reshaping diabetes care. Finally, the webinar concluded with discussions on the protocol for holding GLP-1 medications before surgery to minimize risks.

Keywords

Diabetes Technology

GLP-1

SGLT2

Diabetic Retinopathy

Cardiovascular Benefits

Fenofibrate

Ocular Conditions

Medical Communication